AGUILERA SANHUEZA, XIMENA PAZXIMENA PAZAGUILERA SANHUEZAHORMAZABAL CASTILLO, JUAN PATRICIOJUAN PATRICIOHORMAZABAL CASTILLOVIAL COX, MARIA CECILIAMARIA CECILIAVIAL COXCORTES SALINAS, LINA JIMENALINA JIMENACORTES SALINASGONZALEZ WIEDMAIER, CLAUDIA MARTACLAUDIA MARTAGONZALEZ WIEDMAIERRUBILAR RAMIREZ, PAOLAPAOLARUBILAR RAMIREZAPABLAZA SALINAS, MAURICIO IVÁNMAURICIO IVÁNAPABLAZA SALINASMuriel Ramírez-SantanaGloria IcazaLoreto Nuñez-FranzRubén Quezada-GateMacarena SaidPEREZ ACUÑA, CLAUDIA VERONICACLAUDIA VERONICAPEREZ ACUÑACASTILLO LABORDE, CARLA CECILIACARLA CECILIACASTILLO LABORDECarolina Sacristán RamírezVIAL CLARO, PABLO AGUSTINPABLO AGUSTINVIAL CLARO2023-01-132023-01-132022Aguilera, X., Hormazábal, J., Vial, C., Cortes, L. J., González, C., Rubilar, P., Apablaza, M., Ramírez-Santana, M., Icaza, G., Nuñez-Franz, L., Castillo-Laborde, C., Ramírez-Riffo, C., Pérez, C., Quezada-Gate, R., Said, M., & Vial, P. (2022). Sars-cov-2 neutralizing antibodies in chile after a vaccination campaign with five different schemes. Vaccines, 10(7), 1051. https://doi.org/10.3390/vaccines10071051https://repositorio.udd.cl/handle/11447/7421https://investigadores.udd.cl/handle/123456789/540310.3390/vaccines100710512-s2.0-85133548389WOS:000831717000001<jats:p>Using levels of neutralizing antibodies (nAbs), we evaluate the successful Chilean SARS-CoV-2 vaccine campaign, which combines different vaccine technologies and heterologous boosters. From a population-based study performed in November 2021, we randomly selected 120 seropositive individuals, organized into six groups of positive samples (20 subjects each) according to natural infection history and the five most frequent vaccination schemes. We conclude that the booster dose, regardless of vaccine technology or natural infection, and mRNA vaccines significantly improve nAbs response.</jats:p>Resource Types::text::journal::journal article